NCT04349280View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Neoplasms
Interventions
DRUG

Bintrafusp alfa

Participants will receive bintrafusp alfa.

Trial Locations (12)

11041

GSK Investigational Site, Lake Success

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

31059

GSK Investigational Site, Toulouse

33000

GSK Investigational Site, Bordeaux

41013

GSK Investigational Site, Seville

45229

GSK Investigational Site, Cincinnati

86021

GSK Investigational Site, Poitiers

94805

GSK Investigational Site, Villejuif

M5G 2M9

GSK Investigational Site, Toronto

1066 CX

GSK Investigational Site, Amsterdam

08035

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT04349280 - A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer | Biotech Hunter | Biotech Hunter